Altria Group (NYSE:MO) closed Friday at $73.79, gaining 0.79% on the day and extending a five-session winning streak that has pushed the stock to within 1% of its 52-week high. The rally, which saw shares climb approximately 6.8% for the week, added about $7.8 billion to the company's equity value, based on 1.67 billion shares outstanding. This performance stands in stark contrast to the broader market, as the S&P 500 lost 2.05% over the same period.
Friday's trading volume spiked to 15.7 million shares, 75% above the 65-day average, though the Russell index reset may have contributed to the elevated activity. FTSE Russell noted that the June 2026 rebalancing began after the close on June 26 and would continue into the open on June 29, potentially distorting volume data for NYSE-listed names like Altria.
The stock's surge has compressed its dividend yield. With a quarterly dividend of $1.06 per share, the annualized yield fell to approximately 5.75%, down from about 6.13% at the end of the prior week. The dividend, announced in May, is payable on July 10 to shareholders of record as of June 15. At its current price, Altria trades at a price-to-earnings ratio of 15.4.
Altria's rally outpaced the S&P 500 by nearly 8.8 percentage points for the week, a notable move for a defensive stock with a beta of just 0.46, suggesting that buyers were specifically targeting the tobacco giant rather than simply mirroring index movements. The broader market struggled, with the S&P 500 slipping 0.05% on Friday and the Nasdaq dropping 4.7% for the week, according to Reuters. David Stubbs, chief investment strategist at AlphaCore Wealth Advisory, told Reuters that concerns about tech profits and spending are "not going away."
FDA Proposes New Rules for Foreign Manufacturers
The U.S. Food and Drug Administration on Friday proposed a new rule requiring foreign tobacco manufacturers to register their facilities and list their products sold in the United States. Domestic companies already comply with these requirements, but foreign firms have been exempt unless specifically ordered by the FDA. The proposed rule is open for public comment until September 14.
"All companies selling tobacco products in the United States should play by the same rules," said Bret Koplow, acting director of the FDA's Center for Tobacco Products, in a statement. The move could have significant implications for Altria, which has long cited illicit and imported nicotine products as headwinds to its business. In its first-quarter report, Altria noted that illegal disposable e-vapor products have negatively impacted consumption and shipment volumes for its own e-vapor subsidiary, NJOY, which holds FDA marketing granted orders for its products.
Outlook and Market Context
Altria's 2026 outlook remains cautious, with the company forecasting adjusted diluted earnings per share in the range of $5.56 to $5.72. The forecast assumes that NJOY ACE will not return to shelves this year. First-quarter adjusted EPS rose 7.3%, and then-CEO Billy Gifford described the quarter as a "strong start to the year."
Looking ahead, the Russell rebalance will continue into Monday's open, and the New York Stock Exchange will be closed on Friday, July 3, for the Independence Day holiday. Investors will be watching for further regulatory developments and any impact on Altria's competitive position as the FDA's proposed rule moves through the comment period.
